Home » Newsletters » BioWorld Science

BioWorld Science

June 25, 2010

View Archived Issues

Sorafenib exhibits antitumor activity in hematological malignancies in phase I trial

S1RA shows promise as analgesic for neuropathic pain

Merck & Co. claims new angiotensin AT receptor antagonists

VIA Pharmaceuticals discloses new DGAT inhibitors

Organon discovers new cannabinoid CB2 receptor agonists

New B-raf kinase inhibitors claimed by Korean scientists

Otsuka identifies new quinolone compounds for Parkinson's disease

Temsirolimus is safe in children with neuroblastoma, high-grade glioma and rhabdomyosarcoma

CYP3A4 inducers and presence of food affect lurasidone exposure

Genentech suspends development of MTRX-1011A in rheumatoid arthritis

TRC-093 shows promise in phase I trial in patients with solid tumors

ViroPharma files PAS with FDA for Cinryze

Dyax and Sigma-Tau partner on DX-88 for HAE and other indications

OMJPI and Diamyd join to develop diabetes therapy rhGAD65

Mologen provides update on clinical status of MGN-1601 and MGN-1703

Pfizer withdraws Mylotarg from U.S. market due to safety concerns

Neurologix phase II trial shows efficacy of NLX-P101 in PD

MJFF provides funds for Ceregene's phase II CERE-120 trial

Nereus completes enrollment in phase II plinabulin trial in lung cancer

Novo Nordisk restarts phase III development of liraglutide for obesity

Takeda announces U.S. launch of ACTOplus met XR

FDA approves Lucentis for macular edema following retinal vein occlusion

QLT reports on Visudyne-Lucentis combination in wet AMD

Medivir and GSK to market Xerclear for treatment of cold sores

GSK and Prosensa expand development of DMD treatments

Tolera's TOL-101 receives orphan drug status for type 1 diabetes

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...